U S Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, Maryland. 2017;2:337-350.
Cardiovascular and noncardiovascular mortality among patients starting dialysis.
JAMA. 2009; 302: 1782-1789
Cardiovascular mortality in end-stage renal disease.
Am J Med Sci. 2003; 325: 163-167
Clinical epidemiology of cardiovascular disease in chronic kidney disease.
J Ren Care. 2010; 36: 4-8
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
New Engl J Med. 2009; 360: 1395-1407
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
New Engl J Med. 2005; 353: 238-248
Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.
Lancet. 2015; 385: 2047-2056
Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.
Kidney Int. 1999; 55: 648-658
Inflammation and cardiovascular risk in dialysis patients.
Kidney Int. 2002; 61: S99-S102
Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy.
Am J Kidney Dis. 2003; 42: 286-294
Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.
Am J kidney Dis. 1998; 32: 107-114
Factors predicting malnutrition in hemodialysis patients: a cross-sectional study.
Kidney Int. 1998; 53: 773-782
Effect of fish oil supplement in maintenance hemodialysis patients: a systematic review and meta-analysis of published randomized controlled trials.
Eur J Clin Pharmacol. 2016; 72: 129-139
Dietary restrictions in dialysis patients: is there anything left to eat?.
InSeminars Dial. 2015; 28: 159-168
The Effect of Omega-3 Supplementation on Serum Inflammatory Factors in Hemodialysis Patients.
BJMMR. 2017; 20: 1-7
Effects of omega-3 fatty acid supplementation on serum biomarkers, inflammatory agents, and quality of life of patients on hemodialysis.
Iranian J kidney Dis. 2016; 10: 381
The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial.
Eur J Clin Pharmacol. 2014; 70: 655-665
Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease.
Nutr Clin Pract. 2009; 24: 508-512
Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients—a pilot study.
Nephrol Dial Transplant. 2007; 22: 3561-3567
Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition–inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients.
Int Urol Nephrol. 2016; 48: 1887-1895
Omega-3 fatty acids inhibit the up-regulation of endothelial chemokines in maintenance hemodialysis patients.
Nephrol Dial Transplant. 2014; 30: 266-274
Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients.
Ann Nutr Metab. 2011; 58: 197-202
Plasma levels of marine n-3 fatty acids are inversely correlated with proinflammatory markers sTNFR1 and IL-6 in renal transplant recipients.
J Ren Nutr. 2017; 27: 161-168
Omega-3 fatty acid supplementation is associated with oxidative stress and dyslipidemia, but does not contribute to better lipid and oxidative status on hemodialysis patients.
J Ren Nutr. 2017; 27: 333-339
Effects of omega-3 fatty acids on markers of inflammation in patients with chronic kidney disease: a controversial issue.
Ther Apher Dial. 2018; 22: 124-132
Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients.
J Ren Nutr. 2007; 17: 296-304
Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients.
Vasc Health Risk Manag. 2012; 8: 187
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.
BMJ. 2011; 343: d5928
Meta-analyses involving cross-over trials: methodological issues.
Int J Epidemiol. 2002; 31: 140-149
Measuring inconsistency in meta-analyses.
BMJ (Clinical research ed). 2003; 327: 557-560
A measure to aid in the interpretation of published clinical trials.
Stat Med. 1985; 4: 1-9
Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences.
Am J kidney Dis. 2003; 42: 864-881